TransMedics Group’s (TMDX) “Hold” Rating Reiterated at Needham & Company LLC

Needham & Company LLC reissued their hold rating on shares of TransMedics Group (NASDAQ:TMDX) in a research note published on Wednesday morning,Benzinga reports.

Other analysts have also recently issued reports about the company. Oppenheimer reissued an “outperform” rating and set a $125.00 price objective on shares of TransMedics Group in a report on Tuesday, December 3rd. Baird R W raised TransMedics Group to a “strong-buy” rating in a report on Tuesday, September 24th. Canaccord Genuity Group dropped their price objective on TransMedics Group from $109.00 to $104.00 and set a “buy” rating for the company in a report on Wednesday, November 20th. Robert W. Baird dropped their price objective on TransMedics Group from $150.00 to $120.00 and set an “outperform” rating for the company in a report on Wednesday. Finally, Piper Sandler dropped their price objective on TransMedics Group from $110.00 to $90.00 and set an “overweight” rating for the company in a report on Wednesday. Two research analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $126.80.

TransMedics Group Stock Down 2.2 %

Shares of NASDAQ TMDX opened at $64.26 on Wednesday. The business has a fifty day moving average of $97.26 and a two-hundred day moving average of $131.98. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. TransMedics Group has a 52-week low of $63.42 and a 52-week high of $177.37. The stock has a market cap of $2.16 billion, a PE ratio of 68.36 and a beta of 2.06.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings results on Monday, October 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The business had revenue of $108.76 million during the quarter, compared to the consensus estimate of $115.00 million. During the same period in the prior year, the firm earned ($0.12) earnings per share. The business’s quarterly revenue was up 63.7% compared to the same quarter last year. As a group, equities research analysts expect that TransMedics Group will post 1 earnings per share for the current fiscal year.

Insider Buying and Selling at TransMedics Group

In other TransMedics Group news, CEO Waleed H. Hassanein sold 8,625 shares of the company’s stock in a transaction on Monday, September 16th. The stock was sold at an average price of $153.42, for a total value of $1,323,247.50. Following the transaction, the chief executive officer now directly owns 61,643 shares of the company’s stock, valued at $9,457,269.06. This represents a 12.27 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Tamer I. Khayal sold 2,958 shares of the company’s stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $148.24, for a total value of $438,493.92. Following the completion of the transaction, the insider now directly owns 20,843 shares in the company, valued at approximately $3,089,766.32. This represents a 12.43 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 28,042 shares of company stock valued at $3,563,985 in the last ninety days. 7.00% of the stock is currently owned by corporate insiders.

Institutional Trading of TransMedics Group

Several large investors have recently modified their holdings of the stock. Wilmington Savings Fund Society FSB acquired a new stake in shares of TransMedics Group during the 3rd quarter worth $149,000. Sanctuary Advisors LLC boosted its stake in TransMedics Group by 63.4% in the third quarter. Sanctuary Advisors LLC now owns 4,041 shares of the company’s stock valued at $634,000 after buying an additional 1,568 shares in the last quarter. Morse Asset Management Inc acquired a new stake in TransMedics Group in the third quarter valued at about $823,000. Virtu Financial LLC acquired a new stake in TransMedics Group in the third quarter valued at about $436,000. Finally, Neo Ivy Capital Management acquired a new stake in TransMedics Group in the third quarter valued at about $554,000. 99.67% of the stock is owned by institutional investors and hedge funds.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.